Journal
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 17, Issue 3, Pages 490-499Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-07-2714
Keywords
-
Funding
- NATIONAL CANCER INSTITUTE [R01CA109193, R03CA110822] Funding Source: NIH RePORTER
- NCI NIH HHS [R03-CA110822, R01-CA109193] Funding Source: Medline
Ask authors/readers for more resources
Head and neck cancer (HNC) patients have variable prognoses even within the same clinical stage and while receiving similar treatments. The number of studies of genetic polymorphisms as prognostic factors of HNC outcomes is growing. Candidate polymorphisms have been evaluated in DNA repair, cell cycle, xenobiotic metabolism, and growth factor pathways. Polymorphisms of XRCC1, FGFR, and CCND1 have been consistently associated with HNC survival in at least two studies, whereas most of the other polymorphisms have either conflicting data or were from single studies. Heterogeneity and lack of description of patient populations and lack of accounting for multiple comparisons were common problems in a significant proportion of studies. Despite a large number of exploratory studies, large replication studies in well-characterized HNC populations are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available